Syntropic develops a non-invasive and non-pharmaceutical treatment for mental health disorders. Through light stimulation, neural remodeling is activated by instructing the immune cells of the brain to support in healing and recovery.
Solgate’s founders combine deep expertise in the biology of solute carriers with unique chemistry-based approaches for accelerated drugging of difficult targets. Current projects are focused on CNS and immunology indications.
Neurolentech is a spinoff of ISTA (Institute of Science and Technology Austria) focused on personalized medicine for neurodevelopmental disorders. The company is developing and characterizing libraries of patient-derived neuronal cells, and will leverage this unique resource for the development of novel therapeutics to tackle severe forms of autism and epilepsy.
